Reimagining Alzheimer’s Disease: New Thinking, New Choices



Date & Location
Tuesday, January 4, 2022, 2:00 PM - Tuesday, January 3, 2023, 11:59 PM

Credits
AMA PRA Category 1 Credits™ (0.50 hours), AMA PRA Category 1 Credits™ Designated (0.50 hours)

Target Audience
Specialties - Family Medicine, Geriatric Medicine, Integrative Medicine, Neurology and Rehabilitation, Primary Care, Psychiatry and Behavioral Health
Professions - Non-Physician, Nurse, Nurse Practitioner, Other Healthcare Professionals, Physician, Physician Assistant/Associate, Physicians In Training, Psychologist, Resident Physician

Overview

Alzheimer’s disease (AD) is an irreversible, age-related, neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living. It is the most common cause of dementia worldwide and its’ prevalence continues to grow in part because of the aging world population. AD is characterized classically by two hallmark pathologies: B-amyloid plaque deposition and neurofibrillary tangles of hyperphosphorylated tau. Diagnosis is based upon clinical presentation fulfilling several criteria including fluid and imaging biomarkers. Until recently, current therapies were limited to delaying cognitive decline in some patients, but not treating the underlying causes of the disease nor halting the progression of the disease. This program discusses recent advances in our understanding of the clinical evaluation for early and accurate diagnosis, newly approved and emerging disease-modifying therapies, as well as non-pharmacological strategies for the management of patients with AD.


Registration

There are no fees for participating in and receiving CME credit for this online activity.

To participate in this activity, register with ReachMD.


Objectives

As a result of participating in this activity, participants should be able to:


  1. Incorporate the latest developments, particularly biomarker technology, for accurate, early detection, and proper diagnosis of AD;
  2. Evaluate the therapeutic implications of emerging disease-modifying therapies and other late-state/newly approved strategies in the treatment of AD;
  3. Integrate non-pharmaceutical interventions as part of a treatment plan to enhance outcomes for patients with AD.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and CORE Medical Education, LLC. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material activity for a maximum of .50 AMA PRA Category 1 Credit™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.


Additional Information

Disclosure of Ineligible Relationships (COI) Policy

In accordance with the ACCME Standards for Integrity and Independence and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies (commercial interest) within the last 24-months. If a relevant relationship interest is identified, it is the responsibility of the University of Cincinnati to initiate a mechanism to mitigate the relationship(s). All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence.

Speaker Disclosures

R. Scott Turner, MD, PhD has disclosed the following relevant financial relationships:
Research Support to Georgetown: Biogen, Lilly, Eisai, Roche, Vaccinex, Janssen, Alector Therapeutics.
Consultant: Jupiter Neurosciences, KeifeRx, Re:Cognition Health

John J. Russell, MD (host) has disclosed the following relevant financial relationships:
Speaker and Advisory Board Member: Bayer, GlaxoSmithKline, US Sanofi

Medical Director & Program Planners

CORE Medical Education, LLC
Otto Ratz, MD
Christina Culbert, MSc

CORE Medical Education staff do not have any relevant relationships to report.

University of Cincinnati Continuing Medical Education Office
Rocky Ellis, MD, Professor, Physician Reviewer
Susan P. Tyler, PhD, MEd, CMP, CHCP, Director
Heather Muskopf, Program Manager

University of Cincinnati staff do not have any relevant relationships to report.

Disclaimer Statement
The opinions expressed during the endured activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati or CORE Medical Education. The information is presented for the purpose of advancing the attendees’ professional development.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Neither the University of Cincinnati nor CORE Medical Education, LLC, recommends the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Learner Assurance Statement
The University of Cincinnati is committed to mitigating all conflicts of interest issues that could arise as a result of prospective faculty members’ relationships with ineligible companies. The University of Cincinnati is committed to retaining only those speakers with financial interests that can be mitigated as they relate to the goals and educational integrity of the CME activity.